RS
BMRN icon

R Squared’s BioMarin Pharmaceuticals BMRN Stock Holding History

R Squared’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,064
Closed -$479K – 507
2025
Q4 		$479K Sell
8,064
-781
-9% -$42.5K 0.22% 126
2025
Q3 		$479K Buy
8,845
+1,199
+16% +$68.6K 0.21% 146
2025
Q2 		$420K Buy
7,646
+2,096
+38% +$123K 0.23% 137
2025
Q1 		$392K Buy
5,550
+3,710
+202% +$250K 0.42% 74
2024
Q4 		$121K Buy
+1,840
New +$123K 0.12% 223

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

R Squared's BMRN Position: Q1 2026 in Review

R Squared sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2026, closing a stake of 8,064 shares — an estimated $479K sold.

R Squared first reported a position in BMRN in Q4 2024 and held it in 5 quarters. The position peaked at $479K in Q4 2025. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • R Squared reported no remaining BioMarin Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • R Squared sold 8,064 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $479K.
  • R Squared first reported a position in BioMarin Pharmaceuticals in Q4 2024 and held it in 5 quarters.
  • R Squared's BioMarin Pharmaceuticals position peaked at $479K in Q4 2025.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on R Squared's 13F filing for Q1 2026, filed 29 Apr 2026.